All News

Percutaneous nephrolithotomy is considered the gold standard for the removal of large renal stones. Until recently, however, the procedure's efficacy had not been verified by a clinical study as large as a gold-standard procedure would seem to require.

A new study indicates that existing evidence is insufficient to show that most of the tort reforms sought-with the exception of caps on noneconomic damages-would be effective in reducing malpractice claims frequency and costs and defensive medicine, or improving the supply of health care services and quality of care.

Conflicting data on fascial defect size and port fixity render any perception of surgical advantage per port type as theoretical. Thus, regarding this aspect, the decision to use bladed or non-bladed trocars is likely best left to surgeon preference.

New urology products and services from American Medical Systems, Caris Life Sciences, UROSKOP Omnia, and Covidien.

This list of U.S.-based National Institutes of Health trials is derived from the NIH's database and includes U.S. phase I and II localized prostate cancer trials that are currently recruiting participants. This list is current as of April 28, 2010.

Targets for improving the state of management of advanced prostate cancer include the development of new diagnostic modalities with better performance in detecting recurrent disease, additional monotherapy or combination treatment options, and strategies for mitigating the risks of androgen deprivation therapy.

Newer treatments for male sexual dysfunction highlighted at the 2010 AUA annual meeting are allowing urologists to improve patients' quality of life and satisfaction with treatment.

Over the past 2 decades, the field of urology has made dramatic progress in understanding the etiology and pathophysiology of BPH/lower urinary tract symptoms.

Urology drugs and devices that are in the pipeline from Rexahn Pharmaceuticals, Inc., CytRx Corp., Urigen Pharmaceuticals, Inc., Seattle Genetics, Inc., Agensys, Inc., and Millennium: The Takeda Oncology Co.

The number of urodynamic studies conducted by urologists applying for board certification or recertification more than doubled in less than a decade, with most of the procedures being performed in men with symptoms of urinary obstruction and in women with urinary incontinence.

Teva Pharmaceutical Industries Ltd. and Mylan Inc. have separately announced that they received FDA approval for generic versions of tamsulosin hydrochloride capsules, 0.4 mg, for the treatment of signs and symptoms of BPH.